Since sulfanilamide has come into general use, a number of reports have appeared indicating that jaundice1 and hemolytic anemia2 are toxic effects that may be encountered. One gains the impression from the majority of these reports that such complications are rarely encountered and that they are probably due to drug idiosyncrasy. Long and his associates1g observed but 2 patients with jaundice (without hemolytic anemia) among 408 treated with sulfanilamide. In the material from the same clinic, Wood2b noted that acute anemia developed in 21 of 522 persons to whom the drug was administered. He found the incidence of anemia to be 8.3 per cent in children as compared with 2.4 per cent in adults. He ascribed the anemia in the 21 cases to hemolysis, because of the abrupt appearance of jaundice and urobilinuria. In 8 additional instances a "slow" type of anemia was encountered, which was similar to that previously
WATSON CJ, SPINK WW. EFFECT OF SULFANILAMIDE AND SULFAPYRIDINE ON HEMOGLOBIN METABOLISM AND HEPATIC FUNCTION. Arch Intern Med (Chic). 1940;65(4):825–846. doi:10.1001/archinte.1940.00190100166007
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: